许从飞 教授（博导）

国家级青年人才项目入选者 华南理工大学TCL青年学者

电子邮件:xucf@scut.edu.cn

办公地址：

广州国际校区C1-c409

实验室网站链接：https://www2.scut.edu.cn/nanomedicine/yjtdcy/list.htm

2025-至今，华南理工大学，教授

2019-2024，华南理工大学，副教授

2017-2019，华南理工大学，博士后

2012-2017，中国科学技术大学，博士

生物医学工程（学博、学硕）、生物学（学博、学硕）、材料与化工（工程博士）、药学（专硕）、生物与医药（工程博士）

药物递送；生物材料；基因编辑；基因治疗；肿瘤免疫治疗

主要从事纳米载体构建与生物大分子药物递送领域的研究，共发表SCI论文50余篇，其中以通讯作者或者第一作者在Cell Biomaterials、Nature Communications、Science Bulletin、Advanced Functional Materials、Nano Today、Nano Letters、ACS Nano、Small、Biomaterials等杂志发表SCI论文30余篇，3篇入选ESI高被引论文；申请发明专利14项（已授权4项）；主持基金委优青、面上、广东省杰青等项目，参与国家重点研发计划、广州市重点研发计划等项目；获2021年度广东省自然科学一等奖。

代表性论文：

1.Yue Wang#, Min Yang#, Bao-Yue Zhang, Gui Zhao,Shi-Kun Zhou, Zi-Dong Lu, Cong-FeiXu*, Jun Wang*, Leveraging T-cell-specificfusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells, Cell Biomaterials, 2025, 1, 100011.

2.Chaoran Chen, Yuxi Zhang, Ziyang Cao, Dongdong Li, Yueqiang Zhu, HoujinJing, Yan Li, Fangzheng Li, Cong-FeiXu*,Xianzhu Yang*, JunWang*, Long-TermStorage Stable Vesicle-Like Nanoparticles of Lipid and Polymer for siRNA andmRNA-Mediated Cancer Immunotherapy, AdvancedFunctional Materials, 2024, 34(44), 2406101.

3.Gui Zhao#, Yue Zhang#, Cong-Fei Xu*, Jun Wang*,In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles, Science Bulletin, 2024, 69(3), 354−366.

4.Yue Wang#, Shi-Kun Zhou#, YanWang, Zi-Dong Lu, Yue Zhang, Cong-Fei Xu*, Jun Wang*,Engineering tumor-specific gene nanomedicine to recruit and activate T cellsfor enhanced immunotherapy, NatureCommunications, 2023, 14, 1993.

5.Yue Zhang#, Gui Zhao#, Jing Liu, Hou-Bing Zhang, Yue Wang, Ying-LiLuo, Zi-Dong Lu, Xiao-Jiao Du, Song Shen, Jin-Zhi Du, Cong-Fei Xu*,Jun Wang*, Gene-activating nanomedicine for thetumor-oriented infiltration of T cells to enhance immunotherapy against solidtumors, Nano Today, 2023, 52, 101992.

6.Yue Zhang#, Gui Zhao#, Yi-Fang Chen, Shi-KunZhou, Yue Wang, Yi-Qun Sun, Song Shen, Cong-Fei Xu*, Jun Wang*,Engineering nano-clusteredmultivalent agonists to cross-link TNF receptors for cancer therapy, Aggregate, 2023, 4(6), e393.

7.Jia Shi#, Meng-Wen Huang#, Zi-Dong Lu, Xiao-Jiao Du,Song Shen, Cong-Fei Xu*, Jun Wang*, Delivery ofmRNA for regulating functions of immune cells, Journal of ControlledRelease, 2022, 345, 494−511.

8.Yue Zhang#, Song Shen#, Gui Zhao, Cong-Fei Xu*, Hou-Bing Zhang, Ying-Li Luo,Zhi-Ting Cao, Jia Shi, Zhi-Bin Zhao, Zhe-Xiong Lian, Jun Wang*, In situ repurposing of dendritic cells withCRISPR/Cas9-based nanomedicine to induce transplant tolerance, Biomaterials,2019, 217, 119302.

9.Cong-Fei Xu#, Dong-Dong Li#, Zhi-Ting Cao, Meng-HuaXiong, Xian-Zhu Yang*, Jun Wang*, Facile hydrophobizationof siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery,Nano Letters, 2019, 19, 2688−2693.

10.Cong-Fei Xu#, Zi-Dong Lu#, Ying-Li Luo, Yang Liu, Zhi-Ting Cao, Song Shen,Hong-Jun Li, Jing Liu, Kai-Ge Chen, Zhi-Yao Chen, Xian-Zhu Yang, Zhen Gu, JunWang*, Targeting of NLRP3 inflammasome with gene editing for the ameliorationof inflammatory diseases, Nature Communications, 2018, 9, 4092.

星光领路人第8期|许从飞：每个行业都有自己的高峰期，而生物医学已至山腰